Bayer might seek settlements in some Monsanto glyphosate-cancer suits, but prepares to fight large claims

Monsanto Bayer x

Bayer AG’s chief executive said …. the company might consider settling lawsuits over Monsanto’s glyphosate-containing weed-killers depending on how high court costs rise, but stressed it remained focused on defending the combined company against claims they cause cancer.

Bayer has asked U.S. District Judge Vince Chhabria, who is overseeing the San Francisco case and some 580 others, to significantly expand the jury pool and question prospective jurors about their knowledge of the media coverage of the cases. Chhabria is expected to decide on the requests in December.

ADVERTISEMENT

In filings …. in San Francisco federal court, where a new glyphosate trial is scheduled to begin on Feb. 25, 2019, Bayer said the “jury pool likely has grown more hostile” due to negative media coverage following the Johnson verdict.

Related article:  Henry Miller: UN glyphosate finding glosses over data to support ideological conclusion

“If we can settle nuisances at some point where the defense costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint,” CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling.

He added: “We will resolutely and with all means defend ourselves in this (glyphosate) litigation.”

ADVERTISEMENT
ADVERTISEMENT

Bayer denies that glyphosate causes cancer and says decades of scientific studies and real-world use have shown the chemical to be safe for human use. The company is appealing the findings.

Read full, original article: Bayer CEO says would consider glyphosate settlement depending on costs

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend